These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9072602

  • 1. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rosenkilde P.
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [Abstract] [Full Text] [Related]

  • 2. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y.
    Urol Int; 2005 Mar; 75(1):43-9. PubMed ID: 16037707
    [Abstract] [Full Text] [Related]

  • 3. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R, Nordle O, Josefsson K.
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA, Boon TA, van de Beek C, Grob P.
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.
    Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T.
    Med Oncol; 2012 Dec; 29(4):2895-900. PubMed ID: 22323054
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    N Engl J Med; 2004 Oct 07; 351(15):1513-20. PubMed ID: 15470214
    [Abstract] [Full Text] [Related]

  • 8. [Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
    Matsuda H, Nonomura K, Nagamori S, Shinohara N, Koyanagi T, Maru A, Matsuno T, Fujieda J, Minami S, Morita H.
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct 07; 86(10):1530-7. PubMed ID: 7474602
    [Abstract] [Full Text] [Related]

  • 9. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group.
    Lancet Oncol; 2007 Nov 07; 8(11):994-1000. PubMed ID: 17942366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M, Kuramoto H, Ota J, Fujimoto N.
    Int J Urol; 2006 Jul 07; 13(7):1019-21. PubMed ID: 16882080
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of hormone-refractory prostate cancer with estramustine phosphate].
    Morote J, López-Pacios MA, Ahmad A, Vila J, de Torres JA.
    Actas Urol Esp; 1991 Jul 07; 15(5):421-4. PubMed ID: 1725472
    [Abstract] [Full Text] [Related]

  • 16. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.
    Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alfthan O.
    Eur Urol; 1991 Jul 07; 19(1):12-5. PubMed ID: 1706666
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.